Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2017 Dec 18.

Published in final edited form as: JAMA Psychiatry. 2016 Aug 1;73(8):779–788. doi: 10.1001/jamapsychiatry.2016.1128

Table 1.

Demographic Characteristics

Variable	D-Cycloserine Plus CBT (n = 70)	Placebo Plus CBT (n = 72)	P Value
Age, mean (SE), y	13.05 (2.93)	12.54 (3.04)	.31^a
Female sex, No. (%)	42 (60.0)	34 (47.2)	.13^b
White race/ethnicity, No. (%)	61 (87.1)	65 (90.3)	.55^b
CY-BOCS at randomization, mean (SE)	24.74 (5.91)	23.96 (4.91)	.39^a
Overall comorbidities, No. (%)
OCD only	11 (15.9)	13 (18.6)
OCD and 1 additional	26 (37.7)	15 (21.4)	.14^c
OCD and 2 additional	13 (18.8)	22 (31.4)	.14^c
OCD and 3 or more	19 (27.5)	20 (28.6)
Specific comorbid conditions, No. (%)
Generalized anxiety disorder	18 (26.1)	23 (31.4)	.49^b
Socialphobia	6 (23.2)	9 (12.7)	.10^b
Attention-deficit/hyperactivity disorder	20 (29.4)	17 (23.6)	.44^b
Depressive disorder	11 (15.9)	10 (13.9)	.73^b
Separation anxiety disorder	9 (13.2)	4 (5.6)	.12^b
Psychotropic medication, %
Serotonin reuptake inhibitor	17 (24.3)	25 (34.7)	.17^b
Atypicalantipsychotic	0	3 (4.2)	.08^b
Stimulant	4(5.7)	3 (4.2)	.67^b

Abbreviations: CBT, cognitive behavior therapy; CY-BOCS, Children’s Yale-Brown Obsessive Compulsive Scale; OCD, obsessive-compulsive disorder.

^a

Analysis of variance F_1,140.

^b

$χ_{1}^{2}$ Test.

^c

$χ_{3}^{2}$ Test.